2026 – State Expert Center of the Ministry of Health of Ukraine

Blokpain, solution for injection, PJSC "Lekhim-Kharkiv"

30.09.2026 40

Summary of the risk management plan for the medicinal product Blokpain, solution for injection, manufactured by PJSC "Lekhim-Kharkiv". The document contains an overview of the epidemiology of postoperative pain, results of literature data on the efficacy and safety of ketorolac in the relief of acute pain, and a statement of the absence of unknown data on treatment efficacy. compiled automatically

Apolitset, tablets, PJSC "Pharmaceutical Firm "Darnytsia"

30.09.2026 62

Summary of the risk management plan for a medicinal product based on levocetirizine dihydrochloride for the symptomatic treatment of allergic rhinitis and urticaria in adults and children from 6 years of age. Contains an overview of the epidemiology of the diseases and a summary of the results of clinical studies of efficacy and safety. compiled automatically

Feiba, powder and solvent for solution for infusion, Takeda Manufacturing Austria AG, Austria

30.09.2026 51

Summary of the risk management plan for the medicinal product Feiba (human plasma protein with activity that bypasses factor VIII inhibitors), version 13.0. The document describes the important risks of the product, measures for their minimisation and monitoring, and is intended for healthcare professionals and patients. compiled automatically

Bilastine-Darnytsia, tablets, PJSC "Pharmaceutical Firm "Darnytsia"

30.09.2026 54

Summary of the risk management plan for the medicinal product Bilastine-Darnytsia, tablets, 20 mg, containing bilastine. The document describes the important risks of the product, measures for their minimisation and planned studies to obtain additional safety information. compiled automatically

Seknidoks, film-coated tablets, WORLD MEDICINE LLC, Ukraine

30.09.2026 48

Summary of the risk management plan for a medicinal product based on secnidazole in the form of tablets of 1,0 g: the indications for use, important risks, measures for their minimisation and further monitoring are described. The document is intended for healthcare professionals and patients. compiled automatically

Fersinol, solution for injection, WORLD MEDICINE LLC, Ukraine

30.09.2026 49

Summary of the risk management plan for a medicinal product based on iron (III) hydroxide polymaltose complex for parenteral use in iron-deficiency anaemia. The document describes the important risks of the medicinal product, measures for their minimisation and further pharmacovigilance. compiled automatically

Ticagrelor-Teva, film-coated tablets, Teva Ukraine LLC, Ukraine

30.09.2026 46

Summary of the risk management plan for the medicinal product Ticagrelor-Teva (tablets 60 mg and 90 mg): important risks in use, measures for their minimisation and missing information are described. Intended for healthcare professionals and patients. compiled automatically

Altreno, lotion, Bausch Health LLC, Ukraine

30.09.2026 52

Summary of the risk management plan for a medicinal product for the treatment of acne in adults, adolescents and children from 9 years of age. Important risks, measures for their minimisation and methods for obtaining additional safety information are described. compiled automatically

Synrise, powder and solvent for solution for injection, Takeda Manufacturing Austria AG, Austria

30.09.2026 48

Summary of the risk management plan for the medicinal product Cinryze (human C1 esterase inhibitor), version 11.2 dated 31 March 2025. The document describes important risks, measures for their minimisation and methods for obtaining additional information, as well as indications for use for the treatment and prevention of hereditary angioedema. compiled automatically

HELPEX® LAR, throat rinse, solution, Mowi Health GmbH

30.09.2026 33

Summary of the risk management plan for a medicinal product for gargling based on chlorhexidine and benzydamine, intended for the treatment of inflammatory and infectious diseases of the oral cavity and pharynx. The document describes important risks, measures for their minimisation and routine pharmacovigilance activities. compiled automatically